Enfusion (NYSE:ENFN) Sees Unusually-High Trading Volume – Here’s Why

Shares of Enfusion, Inc. (NYSE:ENFN) saw unusually-high trading volume on Thursday . Approximately 1,375,855 shares changed hands during trading, an increase of 2% from the previous session’s volume of 1,346,222 shares.The stock last traded at $10.96 and had previously closed at $10.92.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ENFN. Piper Sandler raised their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. William Blair reiterated a “market perform” rating on shares of Enfusion in a research report on Monday. Finally, Stifel Nicolaus upped their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.25.

Enfusion Price Performance

The company has a market cap of $1.41 billion, a PE ratio of 273.69, a price-to-earnings-growth ratio of 1.58 and a beta of 0.95. The business has a fifty day simple moving average of $10.22 and a two-hundred day simple moving average of $9.25.

Insider Transactions at Enfusion

In related news, CEO Oleg Movchan sold 2,771 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $28,070.23. Following the transaction, the chief executive officer now owns 526,702 shares in the company, valued at approximately $5,335,491.26. This represents a 0.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,041 shares of company stock valued at $597,367. Corporate insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Several hedge funds have recently added to or reduced their stakes in the business. Centiva Capital LP increased its holdings in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after purchasing an additional 1,227 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares during the last quarter. Azora Capital LP lifted its stake in Enfusion by 6.8% in the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock worth $283,000 after purchasing an additional 1,890 shares in the last quarter. 272 Capital LP increased its holdings in shares of Enfusion by 1.5% in the second quarter. 272 Capital LP now owns 139,180 shares of the company’s stock valued at $1,186,000 after purchasing an additional 2,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Enfusion by 27.7% during the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after buying an additional 4,239 shares during the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.